Literature DB >> 2181621

Endoscopic findings in the stomach and duodenum after treatment with enteric-coated and plain naproxen tablets in healthy subjects.

E Oddsson1, H Gudjonsson, B Thjodleifsson.   

Abstract

To compare the damaging effect of enteric-coated and plain naproxen tablets on the gastric and duodenal mucosa, 12 healthy subjects were studied before and after 2 7-day treatment periods in a randomized, double-blind, double-dummy, crossover trial. Both preparations of the drug caused mucosal lesions, but the extent of the damage was significantly less in the stomach and duodenum after enteric-coated than after plain naproxen tablets. The subjects, however, did not have a preference for either preparation. The morning plasma naproxen concentration was significantly higher after treatment with enteric-coated naproxen than after treatment with plain tablets. The results of the study indicate that naproxen damages the mucosa of the stomach and duodenum through local and systemic effects. The local effect seems to be the more important and can at least be partially prevented by enteric-coating of the tablets.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2181621

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  4 in total

Review 1.  Are perioperative nonsteroidal anti-inflammatory drugs ulcerogenic in the short term?

Authors:  H Kehlet; J B Dahl
Journal:  Drugs       Date:  1992       Impact factor: 9.546

Review 2.  Novel oral drug formulations. Their potential in modulating adverse effects.

Authors:  A T Florence; P U Jani
Journal:  Drug Saf       Date:  1994-03       Impact factor: 5.606

Review 3.  Naproxen. A reappraisal of its pharmacology, and therapeutic use in rheumatic diseases and pain states.

Authors:  P A Todd; S P Clissold
Journal:  Drugs       Date:  1990-07       Impact factor: 9.546

4.  Efficacy and tolerability of diclofenac dispersible in painful osteoarthrosis.

Authors:  R Bakshi; N Ezzet; L Frey; D Lasry; D Salliere
Journal:  Clin Rheumatol       Date:  1993-03       Impact factor: 2.980

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.